DOP2013000085A - Formulacion de capsula - Google Patents

Formulacion de capsula

Info

Publication number
DOP2013000085A
DOP2013000085A DO2013000085A DO2013000085A DOP2013000085A DO P2013000085 A DOP2013000085 A DO P2013000085A DO 2013000085 A DO2013000085 A DO 2013000085A DO 2013000085 A DO2013000085 A DO 2013000085A DO P2013000085 A DOP2013000085 A DO P2013000085A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutically active
liquid
ingredient
solid
capsule formulation
Prior art date
Application number
DO2013000085A
Other languages
English (en)
Inventor
Yoshihiro Uchiyama
Tomochiro Yoshinari
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2013000085A publication Critical patent/DOP2013000085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona la siguiente preparación de cápsula, que es superior en la característica de disolución y similares de un ingrediente farmacéuticamente activo y contiene los ingredientes farmacéuticamente activos líquidos y sólidos: una cápsula transparente que contiene los ingredientes farmacéuticamente activos líquidos y sólidos, en donde el ingrediente líquido farmacéuticamente activo se encapsula en forma de composición farmacéutica líquida, y el ingrediente sólido farmacéuticamente activo se dispersa en una capa de cubierta de cápsula.
DO2013000085A 2008-01-10 2013-04-19 Formulacion de capsula DOP2013000085A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008003634 2008-01-10

Publications (1)

Publication Number Publication Date
DOP2013000085A true DOP2013000085A (es) 2013-06-15

Family

ID=40853060

Family Applications (3)

Application Number Title Priority Date Filing Date
DO2010000214A DOP2010000214A (es) 2008-01-10 2010-07-09 Formulacion de capsula
DO2013000087A DOP2013000087A (es) 2008-01-10 2013-04-19 Formulacion de capsula
DO2013000085A DOP2013000085A (es) 2008-01-10 2013-04-19 Formulacion de capsula

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DO2010000214A DOP2010000214A (es) 2008-01-10 2010-07-09 Formulacion de capsula
DO2013000087A DOP2013000087A (es) 2008-01-10 2013-04-19 Formulacion de capsula

Country Status (21)

Country Link
US (1) US20100285121A1 (es)
EP (3) EP2455070A1 (es)
JP (1) JP5421126B2 (es)
KR (1) KR20100111292A (es)
CN (3) CN101969932A (es)
AU (1) AU2008345848B2 (es)
BR (1) BRPI0822019A2 (es)
CA (1) CA2711814A1 (es)
CO (1) CO6290641A2 (es)
CR (1) CR11625A (es)
DO (3) DOP2010000214A (es)
EA (3) EA201200829A1 (es)
EC (1) ECSP10010395A (es)
IL (1) IL206791A0 (es)
MA (1) MA32027B1 (es)
MX (1) MX2010007609A (es)
MY (1) MY157189A (es)
NZ (3) NZ600720A (es)
UA (3) UA102478C2 (es)
WO (1) WO2009087938A1 (es)
ZA (1) ZA201004793B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
CN102421422A (zh) 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2895477T3 (es) * 2009-10-23 2022-02-21 Basf As Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
US8609138B2 (en) 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
JP5876695B2 (ja) 2011-09-29 2016-03-02 森下仁丹株式会社 シームレスカプセルおよびその製造方法
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
KR20150028233A (ko) * 2012-05-07 2015-03-13 옴테라 파마슈티칼스, 인크. 스타틴 및 오메가-３ 지방산의 조성물
CA2874455C (en) 2012-05-22 2016-10-11 Kuhnil Pharm. Co., Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134466A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3103351B1 (en) * 2014-01-31 2018-11-07 Morishita Jintan Co., Ltd. Orally administered agent for ruminants and ruminant feed containing same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
BR112016030274B1 (pt) * 2014-06-26 2021-01-26 R.P. Scherer Technologies, Llc métodos para fabricação de um material granular encapsulado e secagem de um material de revestimento, e, secador de leito fluidificado
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN104940654A (zh) * 2015-06-24 2015-09-30 黄红林 一种葛根胶囊
KR101950907B1 (ko) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019197961A1 (en) * 2018-04-09 2019-10-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of nintedanib esylate
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5488880A (en) * 1977-10-06 1979-07-14 Eru Emu Asoshieito Yuugen Soft capsule
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
JPS59157018A (ja) * 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS63238015A (ja) * 1987-03-24 1988-10-04 Morishita Jintan Kk 徐放性カプセル製剤
JPH01186815A (ja) * 1988-01-21 1989-07-26 Tokai Kapuseru Kk 軟カプセル剤およびその製造法
JPH01193216A (ja) * 1988-01-29 1989-08-03 Fuji Kapuseru Kk ソフトカプセル及び球状物
JPS6415A (en) * 1988-03-17 1989-01-05 Freunt Ind Co Ltd Absorption-improving drug preparation
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3159724B2 (ja) * 1991-04-19 2001-04-23 フロイント産業株式会社 シームレスカプセル製造方法および装置
JP3144865B2 (ja) * 1991-12-06 2001-03-12 エーザイ株式会社 軟カプセル剤
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
JPH0823912A (ja) * 1994-07-19 1996-01-30 Yoshinobu Umeda アシタバ入り食品
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
JP4309045B2 (ja) * 1997-10-30 2009-08-05 森下仁丹株式会社 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PT1285651E (pt) 2000-04-28 2010-10-21 Takeda Pharmaceutical Antagonistas da hormona concentradora da melanina
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
WO2003094897A1 (en) * 2002-05-09 2003-11-20 Chugai Seiyaku Kabushiki Kaisha Photostabilized soft capsule
KR100490279B1 (ko) * 2002-07-18 2005-05-17 주식회사 서흥캅셀 구취제거 및 구강 청량 효과를 지닌 젤라틴 연질캅셀제
JP4870430B2 (ja) * 2003-06-20 2012-02-08 持田製薬株式会社 下肢静脈瘤予防・治療用組成物
JP2005046054A (ja) * 2003-07-29 2005-02-24 Nippon Kayaku Co Ltd ダイエット食品及びダイエット用製剤
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2005102291A1 (ja) * 2004-04-21 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 水溶性活性成分含有シームレスカプセル
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006073147A1 (ja) * 2005-01-04 2006-07-13 Mochida Pharmaceutical Co., Ltd. 脂肪毒性の改善剤
RU2007139819A (ru) * 2005-03-29 2009-05-10 МакНЕЙЛ-Пи-Пи-Си, ИНК. (US) Композиции с гидрофильными лекарствами в гидрофобной среде
AR054368A1 (es) * 2005-06-01 2007-06-20 Takeda Pharmaceutical Metodo para tratar hiperlipidemia
JP4327872B2 (ja) 2005-10-07 2009-09-09 トヨタ自動車株式会社 複数枚の回路基板を固定する固定部材とそれを利用したモジュール
JP4005104B2 (ja) * 2006-02-07 2007-11-07 持田製薬株式会社 脳卒中再発予防用組成物
WO2007091338A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
CA2655615A1 (en) * 2006-06-26 2008-12-17 Valpharma S.A. A pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
CA2675836C (en) * 2007-01-17 2016-10-11 Mochida Pharmaceutical Co., Ltd. Composition for preventing or treating thrombus- or embolus-associated disease
CN102552213A (zh) * 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊

Also Published As

Publication number Publication date
NZ587019A (en) 2012-07-27
MA32027B1 (fr) 2011-01-03
WO2009087938A1 (ja) 2009-07-16
ZA201004793B (en) 2011-09-28
NZ600720A (en) 2012-12-21
CN103705487A (zh) 2014-04-09
MX2010007609A (es) 2010-08-04
EP2229939A1 (en) 2010-09-22
EA201070835A1 (ru) 2011-02-28
US20100285121A1 (en) 2010-11-11
IL206791A0 (en) 2010-12-30
UA100403C2 (en) 2012-12-25
EP2455070A1 (en) 2012-05-23
EA201200830A1 (ru) 2012-11-30
MY157189A (en) 2016-05-13
EP2229939A4 (en) 2011-04-27
AU2008345848B2 (en) 2014-05-15
AU2008345848A1 (en) 2009-07-16
DOP2013000087A (es) 2014-01-31
NZ600721A (en) 2013-03-28
UA102477C2 (en) 2013-07-10
UA102478C2 (en) 2013-07-10
CN101969932A (zh) 2011-02-09
CO6290641A2 (es) 2011-06-20
ECSP10010395A (es) 2010-09-30
EP2455071A1 (en) 2012-05-23
EA201200829A1 (ru) 2012-11-30
CR11625A (es) 2010-09-29
CA2711814A1 (en) 2009-07-16
CN103705486A (zh) 2014-04-09
BRPI0822019A2 (pt) 2015-07-21
KR20100111292A (ko) 2010-10-14
DOP2010000214A (es) 2010-07-31
JP5421126B2 (ja) 2014-02-19
JPWO2009087938A1 (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
DOP2010000214A (es) Formulacion de capsula
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
CO6731103A2 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
WO2007143652A3 (en) Chewable soft gelatin capsules
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
MX2019013095A (es) Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
AR055631A1 (es) Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada
WO2007075475A3 (en) Gastric reflux resistant dosage forms
UY32624A (es) Procedimiento y composición para mejorar la absorción de agentes terapéuticos
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
MX344163B (es) Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
ITMI20050387A1 (it) Nuove capsule di gelatina molle
EA201170880A1 (ru) Таблетка с контролируемым высвобождением с малой дозой активного вещества
AR076916A1 (es) Medicamento a base de calcio y de vitamina d. kit.
PE20081482A1 (es) Capsulas de gelatina que contienen un acido
TN2010000315A1 (en) Capsule formulation
EA201170950A1 (ru) Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
WO2006122069A3 (en) Formulations of mast cell stabilizing agents for delivery to the colon